tbuckley/cabot-search huggingface dataset:
LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI)
Authors: Y. Loriot, A.V. Balar, D.P. Petrylak, S.T. Tagawa, A. Rezazadeh, A. Fléchon, R. Jain, N. Agarwal, M. Bupathi, P. Barthélémy, P. Beuzeboc, P.L. Palmbos, C.E. Kyriakopoulos, D. Pouessel, C.N. Sternberg, Q. Hong, T. Goswami, L.M. Itri, P. Grivas
Journal: Annals of Oncology (2020)
1591P Whole exome sequencing: Evolution of indications and cost to inform public health policy decision-making
Authors: A. Bayle, N. Droin, B. Besse, Z. Zou, Y. Boursin, S. Rissel, E. Solary, L. Lacroix, E. Rouleau, I. Borget, J. Bonastre
Journal: Annals of Oncology (2020)
1622MO Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
Authors: J.R. Zalcberg, M. Heinrich, S. George, S. Bauer, H. Gelderblom, P. Schöffski, C. Serrano, R.L. Jones, S. Attia, G. D'Amato, P. Chi, P. Reichardt, J.N. Meade, V. Reichert, K. Shi, R. Ruiz-Soto, M. von Mehren, J-Y. Blay
Journal: Annals of Oncology (2020)
LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study
Authors: F. Barlesi, L. Greillier, F. Monville, C. Foa, None J. le Treut, C. Audigier-Valette, F. Vély, S. Garcia, F. Sabatier, J. Ciccolini, M. Fabre, M. Le Ray, N. Resseguier, P. Outters, M. Roumieux, J. Mazieres, M. Pérol, E. Vivier, P. Auquier, J. Fieschi
Journal: Annals of Oncology (2020)
1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma
Authors: O. Hamid, A.M. Joshua, W-J. Hwu, A. Ribas, J. Weber, A.S. Daud, F.S. Hodi, J.D. Wolchok, T.C. Mitchell, P. Hersey, R. Dronca, R.W. Joseph, C. Boutros, L. Min, G.V. Long, J. Schachter, J. Lin, N. Ibrahim, M. Carlino, C. Robert
Journal: Annals of Oncology (2020)
1313P Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC
Authors: M. Nishio, N. Peled, A. Zer, B. Houghton, J. Bar, D. Drew, R. Herbst, D. Rodriguez-Abreu, R. Talpur, L. Golden, L. Yin, T. Dang, R. Hui
Journal: Annals of Oncology (2020)
A Red Light‐Triggered Drug Release System Based on One‐Photon Upconversion‐Like Photolysis
Authors: Wen Lv, Kaiqi Long, Yang Yang, Sijie Chen, Changyou Zhan, Weiping Wang
Journal: Advanced Healthcare Materials (2020)

Photoresponsive drug release systems can enhance drug accumulation at the sites where light is applied. Nowadays, the photocleavable groups used in the systems usually require ultraviolet or blue light irradiation, which limits tissue penetration depth and is harmful to normal cells and living bodies. A one-photon upconversion-like photolysis strategy, which can cleave green light-activatable prodrugs with red light at the presence of a red light-excitable photosensitizer in organic solvents, is developed. However, both the prodrug and photosensitizer are hydrophobic and their energy transfer process is sensitive to oxygen molecules. Here, a simple strategy to address these problems by loading the two components in biocompatible and biodegradable polymeric micelles, is presented. The developed low-irradiance red light-triggered drug release system has a size around 40 nm and exhibits good stability in aqueous solutions. The micellar encapsulation protects the photolysis reaction from oxygen quenching in normoxia aqueous solutions. The therapeutic effect of the system enhanced by the redlight irradiation is demonstrated through in vitro and in vivo studies, indicating promising potential in cancer therapy. The study provides the first example and also an important reference for applying one-photon upconversion-like photolysis in biomedical applications.
1121P Factors predicting overall survival (OS) and progression-free survival (PFS) in real-life: Classification and regression tree analysis of a 5-year (5Y) cohort follow-up study of advanced melanoma patients (pts) that have initiated pembrolizumab
Authors: P. Saiag, N. Meyer, C. Dutriaux, L. Verdoni, O. Morsli, A. Spampinato, L. Lattenist, L. Mortier, J-J. Grob
Journal: Annals of Oncology (2020)
LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
Authors: G. Bianchini, C-S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, S. Russo, E.M. Ciruelos, R. Greil, V. Semiglazov, M.A. Colleoni, C.M. Kelly, G. Mariani, L. Del Mastro, C. Smart, P. Valagussa, G. Viale, L. Gianni
Journal: Annals of Oncology (2020)
1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study
Authors: B. Jori, O. Gautschi, M. Kimmich, S. Beaucaire Danel, N. Reinmuth, P. Garrido Lopez, F. Cappuzzo, M. Forster, K. Patel, C. Grohe, A. Müller, C. Wesseler, R. Menon, J. Müller, E. Mariotti, J. Brinkmann, L. Heukamp, F. Griesinger
Journal: Annals of Oncology (2020)
1015TiP Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An expansion cohort of the phase III REACH-2 study
Authors: R.S. Finn, S-K. Qin, P.R. Galle, C. Wang, K.D. Ogburn, R. Widau, A.X. Zhu
Journal: Annals of Oncology (2020)
1189O Validation of whole genome sequencing in routine clinical practice
Authors: K. Monkhorst, K. Samsom, L. Schipper, P. Roepman, L. Bosch, E. de Bruijn, L.R. Hoes, I. Riethorst, L. Schoenmaker, L. van der Kolk, T. Buffart, K. van der Hoeven, E.E. Voest, E. Cuppen, G. Meijer
Journal: Annals of Oncology (2020)
1950P TRANSLATE: Activation of immune response in refractory patients to standard treatment
Authors: M.C. Merlano, M. Paccagnella, O. Garrone, A. Falletta, E. Fea, A. Abbona, C. Lo Nigro, L. Gammaitoni, P. Vanella, M. Monteverde, C. Granetto, M. Occelli, N. Denaro, A. Merlotti, A. Reali, D. Sangiolo
Journal: Annals of Oncology (2020)
LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
Authors: B. Besse, J. Menis, P. Bironzo, R. Gervais, L. Greillier, I. Monnet, L. Livi, R. Young, C. Decroisette, N. Cloarec, G. Robinet, R. Schott, R. Califano, F. De Marinis, G.L. Banna, M. Mauer, A. Pochesci, B. Hasan, T. Berghmans, A-M.C. Dingemans
Journal: Annals of Oncology (2020)
LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
Authors: C. Faivre-Finn, D. Vicente, T. Kurata, D. Planchard, L. Paz-Ares, J.F. Vansteenkiste, D.R. Spigel, M.C. Garassino, M. Reck, S. Senan, J. Naidoo, A. Rimner, Y-L. Wu, J.E. Gray, M. Özgüroğlu, K.H. Lee, M. Newton, L. Wang, P. Thiyagarajah, S.J. Antonia
Journal: Annals of Oncology (2020)
1460P Impact of sites of metastatic dissemination on survival in advanced gastroesophageal adenocarcinoma
Authors: X. Wang, O. Espin-Garcia, C. Suzuki, Y. Bach, D. Jiang, L.X. Ma, M.J. Allen, M.X. Honório, E. Chen, G. Darling, J.C-W. Yeung, R. Wong, P. Veit-Haibach, K. Sangeetha, R.W-J. Jang, E. Elimova
Journal: Annals of Oncology (2020)
1856P Clinical relevance of pancreatic enzyme replacement therapy (PERT) in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy
Authors: U. Peretti, I. Trestini, L. Carbognin, I. Sperduti, A. Caldart, D. Melisi, A. Auriemma, C. Soldà, D. Tregnago, A. Avancini, S. Pilotto, E. Bria, G. Tortora, M. Reni, M. Milella
Journal: Annals of Oncology (2020)
Osteopontin Takes Center Stage in Chronic Liver Disease
Authors: Zhuolun Song, Wei Chen, Dipti Athavale, Xiaodong Ge, Romain Desert, Sukanta Das, Hui Han, Natalia Nieto
Journal: Hepatology (2020)

Osteopontin (OPN) was first identified in 1986. The prefix osteo‐ means bone; however, OPN is expressed in other tissues, including liver. The suffix ‐pontin means bridge and denotes the role of OPN as a link protein within the extracellular matrix. While OPN has well‐established physiological roles, multiple “omics” analyses suggest that it is also involved in chronic liver disease. In this review, we provide a summary of the OPN gene and protein structure and regulation. We outline the current knowledge on how OPN is involved in hepatic steatosis in the context of alcoholic liver disease and non‐alcoholic fatty liver disease. We describe the mechanisms whereby OPN participates in inflammation and liver fibrosis and discuss current research on its role in hepatocellular carcinoma and cholangiopathies. To conclude, we highlight important points to consider when doing research on OPN and provide direction for making progress on how OPN contributes to chronic liver disease.
Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials
Authors: Christopher E Brightling, Mina Gaga, Hiromasa Inoue, Jing Li, Jorge Maspero, Sally Wenzel, Samopriyo Maitra, David Lawrence, Florian Brockhaus, Thomas Lehmann, Caterina Brindicci, Barbara Knorr, Eugene R Bleecker
Journal: The Lancet Respiratory Medicine (2020)
Academic GP who tried to hide his outside work has suspension extended to 12 months
Authors: Clare Dyer
Journal: BMJ (2020)

A professor of general practice who was suspended from the UK medical register last year for trying to hide the extent of his outside work from his employers has had his suspension extended from six months to 12 after the General Medical Council (GMC) appealed to the High Court against a ruling it considered too lenient.

In June 2019 a medical practitioners tribunal found that Robert Walton had been dishonest with his employers when they quizzed him about his outside working arrangements eight months after he took up a post at Warwick University’s medical school.1 He had told them that he was working one day a week at another job, when he was actually working as many as three days a week at two other …
365MO Exploring changes in glioblastoma treatment patterns in Europe and the USA with population-based cancer registry data
Authors: F. Giusti, M.D.C. Martos, S. Scoccianti, L. Neamtiu, G. Randi, M. Flego, T.A. Dyba, R. Negrao De Carvalho, N. Dimitrova, N. Nicholson, M. Bettio
Journal: Annals of Oncology (2020)
11P Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions
Authors: Y. Nagamoto, M. Miyamoto, N. Togashi, T. Taira, T. Jimbo, T. Isoyama, M. Takahashi, K. Takeuchi, K-I. Yoshida, S. Higuchi, T. Seki, Y. Abe
Journal: Annals of Oncology (2020)
554P Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study
Authors: K.Z. Thein, A.M. Tsimberidou, S. Piha-Paul, F. Janku, D.D. Karp, S. Fu, A. Zarifa, J. Gong, T.A. Yap, D.S. Hong, V. Subbiah, S. Pant, F. Meric-Bernstam, A. Naing
Journal: Annals of Oncology (2020)
2O Growth differentiation factor 15 (GDF-15) neutralization reverses cancer cachexia, restores physical performance and mitigates emesis associated with platinum-based chemotherapy
Authors: Z. Wu, D. Bennett, J. Brosnan, R.A. Calle, S. Collins, R. Esquejo, S. Joaquim, A. Joyce, H. Kim, B. LaCarubba, L. Lin, J.Y. Kim-Muller, M. Peloquin, B. Pettersen, S. Qiao, M. Rossulek, G. Weber, B. Zhang, M. Birnbaum, D. Breen
Journal: Annals of Oncology (2020)
1818MO Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? Intermediate results from the MeTHOS study
Authors: S. Xynogalos, D. Symeonidis, G. Papageorgiou, N. Charalambakis, E. Lianos, C. Kosmas, P. Manikis, G. Vorgias, N. Ziras
Journal: Annals of Oncology (2020)
1831P Role of body composition (bc) in advanced non-small cell lung cancer (NSCLC) patients receiving first-line pembrolizumab (pembro)
Authors: S. Pilotto, I. Trestini, I. Sperduti, M. Sposito, D. Kadrija, A. Dodi, M. Cintoni, A. Drudi, G. Aluffi, L. Belluomini, G. Sartori, M. Casali, F. Lombardo, D. Tregnago, A. Avancini, L. Carbognin, M. D'Onofrio, M.C. Mele, E. Bria, M. Milella
Journal: Annals of Oncology (2020)
509P A different epidemiological trend in Brazilian early-onset colorectal cancer (EOCRC): Real-world data from a reference cancer center
Authors: A.I.M. Kazzi, T.D.M. Passarini, F.A. Duarte, F.R. Paes, B.L. Ferrari, A.A.D.A. Jacome
Journal: Annals of Oncology (2020)
1690P Development of a model to predict hospital admission and severe outcome in cancer patients with COVID-19
Authors: R. Lee, C. Zhou, R. Shotton, A. Tivey, E. Dickens, P. Huddar, H. McKenzie, H. Boyce, A. Maynard, M.P. Rowe, S. Khan, L. Eastlake, A. Angelakas, M. Baxter, E. Copson, L. Horsley, A. Thomas, C. Wilson, T. Cooksley, A. Armstrong
Journal: Annals of Oncology (2020)
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTIC‐HF</scp> baseline characteristics and comparison with contemporary clinical trials
Authors: John R. Teerlink, Rafael Diaz, G. Michael Felker, John J.V. McMurray, Marco Metra, Scott D. Solomon, Kirkwood F. Adams, Inder Anand, Alexandra Arias‐Mendoza, Tor Biering‐Sørensen, Michael Böhm, Diana Bonderman, John G.F. Cleland, Ramon Corbalan, Maria G. Crespo‐Leiro, Ulf Dahlström, Luis E. Echeverria Correa, James C. Fang, Gerasimos Filippatos, Cândida Fonseca, Eva Goncalvesova, Assen R. Goudev, Jonathan G. Howlett, David E. Lanfear, Mayanna Lund, Peter Macdonald, Vyacheslav Mareev, Shin‐ichi Momomura, Eileen O'Meara, Alexander Parkhomenko, Piotr Ponikowski, Felix J.A. Ramires, Pranas Serpytis, Karen Sliwa, Jindrich Spinar, Thomas M. Suter, Janos Tomcsanyi, Hans Vandekerckhove, Dragos Vinereanu, Adriaan A. Voors, Mehmet B. Yilmaz, Faiez Zannad, Lucie Sharpsten, Jason C. Legg, Siddique A. Abbasi, Claire Varin, Fady I. Malik, Christopher E. Kurtz
Journal: European Journal of Heart Failure (2020)

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class ≥II, ejection fraction ≤35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N‐terminal pro‐B‐type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC‐HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America ( n = 1386), enrolled as inpatients ( n = 2084), systolic blood pressure &lt;100 mmHg ( n = 1127), estimated glomerular filtration rate &lt;30 mL/min/1.73 m 2 ( n = 528), and treated with sacubitril/valsartan at baseline ( n = 1594). Conclusions GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)
Authors: P. Martin Romano, L. Mezquita, L. Lacroix, E. Rouleau, A. Varga, C. Baldini, S. Postel-Vinay, L. Friboulet, A. Geraud, M. Aldea, A. Gazzah, Y. Loriot, J-C. Soria, F. André, A. Hollebecque, B. Besse, C. Massard, A. Italiano
Journal: Annals of Oncology (2020)
234P Germline mutations in index patients with ductal carcinoma in situ (DCIS): A single center retrospective study
Authors: K. Ouali, B. Verret, D. Wehrer, V. Goldbarg, A. Larive, M-L. Joulia, S. Villebasse, M. Di Maria, S. Delaloge, O. Caron
Journal: Annals of Oncology (2020)
1989P Down-regulation of interleukin-related genes SCGB1A1 and IL36A serve as the mechanism of TMB-Low leading to poor immunotherapy efficacy on stomach, cervical, esophageal and lung cancer
Authors: Q. Ding, T. He, D. Chen, L. Li, M. Ge, M. Xiao, S. Li, Y. Wu
Journal: Annals of Oncology (2020)
Abstract 14626: Acute Anti-Inflammatory Effects of Targeted Theranostic PPAR Gamma Activator on the Plaques of Coronary-Sized Artery Using Intravascular Optical Coherence Tomography (OCT)-Near Infrared Fluorescence (NIRF) Structural-Molecular Imaging
Authors: Joon Woo Song, Hyeong Soo Nam, Hyun-Sang Park, Jah Yeon Choi, Jae Won Ahn, Young Dae Joo, Hyun Jung Kim, Yeon Hoon Kim, Wang-Yuhl Oh, Hongki Yoo, Kyeongsoon Park, Jin Won Kim
Journal: Circulation (2018)

Introduction and Hypothesis: Macrophage-rich atherosclerosis is associated with the evolution and destabilization of plaques. In our previous study, macrophage mannose receptor (MMR)-targeted PPARγ...
LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study
Authors: K. de Joode, D. Dumoulin, J. Tol, H. Westgeest, L. Beerepoot, F. Van den Berkmortel, P. Mutsaers, N. van Diemen, O. Visser, H.J. Bloemendal, H. van Laarhoven, L. Hendriks, J.B.A.G. Haanen, E.G.E. de Vries, A-M.C. Dingemans, A. Van der Veldt
Journal: Annals of Oncology (2020)
879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer
Authors: M.J. Birrer, L.R. Mileshkin, K. Fujiwara, I. Ray-Coquard, J. Alexandre, A. Okamoto, M.R. Mirza, J.L. Gulley, G. Jehl, S. Ramage, L.S. Ojalvo, S.M. Campos
Journal: Annals of Oncology (2020)
983P Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial
Authors: J. Xu, J. Shen, S. Gu, Y. Zhang, L. Wu, J. Wu, G. Shao, Y. Zhang, L. Xu, T. Yin, J. Liu, Z. Ren, J. Xiong, X. Mao, L. Zhang, J. Yang, L. Li, X. Chen, Z. Wang, Q. Wang
Journal: Annals of Oncology (2020)
1118P Retrospective analysis of safety in elderly BRAF V600 mutation-positive advanced melanoma patients treated with dabrafenib (D) and trametinib (T) and correlation with non-elderly patients
Authors: A. García-Castaño, I. González-Barrallo, V.E. Castellón Rubio, J. Medina Martínez, J.L. Manzano Mozo, K. Mujika, M. Majem Tarruella, C. Aguado de La Rosa, M.A. Cabrera Suárez, I. Palacio, L. Osterloh, A. Martinez Fernandez
Journal: Annals of Oncology (2020)
Analysis of mesenchymal stem cell proteomes <i>in situ</i> in the ischemic heart
Authors: Dunzheng Han, Junjie Yang, Eric Zhang, Yanwen Liu, Chan Boriboun, Aijun Qiao, Yang Yu, Jiacheng Sun, Shiyue Xu, Liu Yang, Wenying Yan, Bihui Luo, Dongfeng Lu, Chunxiang Zhang, Chunfa Jie, James Mobley, Jianyi Zhang, Gangjian Qin
Journal: Theranostics (2020)

Rationale: Cell therapy for myocardial infarction is promising but largely unsuccessful in part due to a lack of mechanistic understanding. Techniques enabling identification of stem cell-specific proteomes in situ in the injured heart may shed light on how the administered cells respond to the injured microenvironment and exert reparative effects. Objective: To identify the proteomes of the transplanted mesenchymal stem cells (MSCs) in the infarcted myocardium, we sought to target a mutant methionyl-tRNA synthetase (MetRSL274G) in MSCs, which charges azidonorleucine (ANL), a methionine analogue and non-canonical amino acid, to tRNA and subsequently to nascent proteins, permitting isolation of ANL-labeled MSC proteomes from ischemic hearts by ANL-alkyne based click reaction. Methods and Results: Murine MSCs were transduced with lentivirus MetRSL274G and supplemented with ANL; the ANL-tagged nascent proteins were visualized by bio-orthogonal non-canonical amino-acid tagging, spanning all molecular weights and by fluorescent non-canonical amino-acid tagging, displaying strong fluorescent signal. Then, the MetRSL274G-transduced MSCs were administered to the infarcted or Sham heart in mice receiving ANL treatment. The MSC proteomes were isolated from the left ventricular protein lysates by click reaction at days 1, 3, and 7 after cell administration, identified by LC/MS. Among all identified proteins (in Sham and MI hearts, three time-points each), 648 were shared by all 6 groups, accounting for 82±5% of total proteins in each group, and enriched under mitochondrion, extracellular exosomes, oxidation-reduction process and poly(A) RNA binding. Notably, 26, 110 and 65 proteins were significantly up-regulated and 11, 28 and 19 proteins were down-regulated in the infarcted vs. Sham heart at the three time-points, respectively; these proteins are pronounced in the GO terms of extracellular matrix organization, response to stress and regulation of apoptotic process and in the KEGG pathways of complements and coagulation cascades, apoptosis, and regulators of actin cytoskeleton. Conclusions: MetRSL274G expression allows successful identification of MSC-specific nascent proteins in the infarcted hearts, which reflect the functional states, adaptive response, and reparative effects of MSCs that may be leveraged to improve cardiac repair.
699O Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between clinical outcomes and exploratory biomarkers
Authors: T.B. Powles, Y. Loriot, J. Bellmunt, C.N. Sternberg, S. Sridhar, D.P. Petrylak, R. Tambaro, L.M. Dourthe, C. Alvarez-Fernandez, M. Aarts, X.J. Mu, K.A. Ching, J. Pu, S. Roychoudhury, C.B. Davis, A. di Pietro, P. Grivas
Journal: Annals of Oncology (2020)
1444P Real-world nivolumab safety data from 650 patients with unresectable advanced or recurrent gastric cancer that had progressed after cancer chemotherapy: Summary of post-marketing surveillance in Japan
Authors: N. Boku, K. Yamaguchi, K. Muro, K. Yoshida, H. Baba, S. Tanaka, A. Akamatsu, T. Sano
Journal: Annals of Oncology (2020)
274O Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study
Authors: V. Dieras, B. Arun, H.S. Han, H. Wildiers, M. Friedlander, J.P. Ayoub, S. Puhalla, S. Hudgens, L. Floden, N. Khandelwal, K. Benjamin, R. Kamalakar, D. Maag
Journal: Annals of Oncology (2020)
252P Survival outcomes of BRCA carriers with pregnancy-associated breast cancer (PABC)
Authors: D. Aguilar, A.S. Ferrigno, A. Aranda-Gutierrez, F. Mesa-Chavez, C. De la Garza-Ramos, J.S. Arango-Vasquez, C. Villarreal-Garza
Journal: Annals of Oncology (2020)